Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CYCN 
Cyclerion Therapeutics Inc (CYCN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: CYCN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.83% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.41M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.93 | 52 Weeks Range 1.27 - 9.47 | Updated Date 11/4/2025 |
52 Weeks Range 1.27 - 9.47 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -89.51% | Operating Margin (TTM) -1797.85% |
Management Effectiveness
Return on Assets (TTM) -24.15% | Return on Equity (TTM) -22.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4938208 | Price to Sales(TTM) 2.49 |
Enterprise Value 4938208 | Price to Sales(TTM) 2.49 | ||
Enterprise Value to Revenue 2.27 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 3203310 | Shares Floating 2467574 |
Shares Outstanding 3203310 | Shares Floating 2467574 | ||
Percent Insiders 31.48 | Percent Institutions 11.43 |
Upturn AI SWOT
Cyclerion Therapeutics Inc
Company Overview
History and Background
Cyclerion Therapeutics, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. It focuses on developing treatments for serious diseases by targeting the nitic oxide (NO) pathway.
Core Business Areas
- Central Nervous System (CNS) Programs: Development of therapies for cognitive impairment associated with neuropsychiatric and neurodegenerative diseases.
Leadership and Structure
Peter M. Hecht, Ph.D. serves as President and CEO. The company has a board of directors that oversees its strategic direction.
Top Products and Market Share
Key Offerings
- CY6463A: A novel positive allosteric modulator of soluble guanylate cyclase (sGC) in clinical development for Cognitive Impairment Associated with Schizophrenia (CIAS). Market share data is not publicly available. Competitors include companies developing therapies for cognitive disorders. Revenue from CY6463A is currently nil as it is in clinical development.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on CNS disorders is competitive, with significant unmet needs in cognitive impairment. There is a drive for novel treatments targeting specific pathways.
Positioning
Cyclerion is positioning itself as a leader in NO pathway modulation for CNS disorders, focusing on diseases with limited treatment options.
Total Addressable Market (TAM)
The TAM for cognitive impairment associated with schizophrenia and other neurological disorders is estimated to be several billion dollars annually. Cyclerion's position relative to this TAM depends on the success of CY6463A and other pipeline candidates.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (NO pathway)
- Experienced leadership team
- Focused pipeline on CNS disorders
Weaknesses
- Limited financial resources
- High risk associated with drug development
- Dependence on single lead compound (CY6463A)
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other CNS indications
- Positive clinical trial results for CY6463A
Threats
- Failure of CY6463A in clinical trials
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- ACAD
Competitive Landscape
Cyclerion faces intense competition from established pharmaceutical companies with greater resources and established products. Their advantage lies in their novel approach to CNS disorders.
Growth Trajectory and Initiatives
Historical Growth: Cyclerion's historical growth is limited as it is focused on clinical development. Growth is based on advancement of CY6463A and other pipeline programs.
Future Projections: Future growth is highly dependent on successful clinical trial outcomes and potential partnerships. Analyst estimates are not widely available due to the company's size and risk profile.
Recent Initiatives: Cyclerion has been focused on advancing CY6463A through clinical trials and exploring partnerships to fund further development.
Summary
Cyclerion Therapeutics is a high-risk, high-reward clinical-stage biotech company. Its strength lies in the novelty of its therapeutic target, but it faces challenges related to funding and clinical trial success. Success hinges on CY6463A's potential. Investors should monitor clinical trial data and partnership opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The information is based on publicly available data, which may not be entirely accurate or complete. Investing in biotech companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyclerion Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-04-02 | CEO, President & Director Dr. Regina M. Graul Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.cyclerion.com |
Full time employees 1 | Website https://www.cyclerion.com | ||
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.